logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
返回期刊详情
E

Expert Opinion on Investigational Drugs

IF4.1
论文数3571
被引数5734
期刊论文 3571
发表时间
delete
Targeting the proteasome in Leishmania donovani: developments from preclinical to Phase I and II trials靶向利什曼原虫属唐氏利什曼原虫的蛋白酶体：从临床前研究到I期和II期试验的进展
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-10-21
delete0
PREAI
deleteShyam Sundar; Sarita Singh; Priya Maurya; Vishal Kumar Singh; Rajiv Kumar
delete分享
delete收藏
Evaluating early systemic therapies in the neoadjuvant setting for the treatment of urological cancers评估新辅助治疗中早期全身性疗法对泌尿系统癌症的治疗效果
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-10-12
delete0
PREAI
deletePanagiotis Velissarios Stamatakos; Charalampos Fragkoulis; Nikolaos Kontolatis; Konstantinos Gklinos; Christoforos Kourouniotis; Athanasios Dellis
delete分享
delete收藏
Dual antigen targeting with Talquetamab Plus Teclistamab: a new horizon for extramedullary multiple myeloma?双抗原靶向Talquetamab联合Teclistamab：这是髓外多发性骨髓瘤的新方向吗？
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-10-09
delete0
deleteOAAI
deleteBinish Javed; Shaji Kumar
delete分享
delete收藏
Safety, pharmacokinetics, pharmacodynamics and target-mediated drug disposition modeling of TST002, a sclerostin antibody, in men and postmenopausal women with low bone mineral densityTST002（一种硬化蛋白抗体）在低骨 mineral density 的男性和绝经后女性中的安全性、药代动力学、药效学及靶介导药物处置建模
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-09-22
delete0
PREAI
deleteSufeng Zhou; Xiufen Zhu; Yuchen Sheng; Lu Wang; Feng Shao; Hua Lin
delete分享
delete收藏
Emerging therapeutic strategies and clinical development of investigational agents for conventional chondrosarcoma传统软骨肉瘤的治疗新策略与研究药物的 clinical development
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-09-20
delete0
PREAI
deleteCarlos Torrado; Anthony P. Conley
delete分享
delete收藏
Innovative therapies under clinical development for ALS treatment. Part 2: biologics and natural products肌萎缩侧索硬化症治疗中处于临床开发阶段的创新疗法。第二部分：生物制剂和天然产物
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-09-12
delete0
deleteOAAI
deleteChi-Chen Sarah Huang; Cecilia Sanchez-Santos; Loreto Martinez-Gonzalez; Carmen Gil; Ana Martinez
delete分享
delete收藏
Varespladib for snakebite envenoming: insights from therapeutic development and clinical trialsVarespladib用于蛇咬中毒：来自治疗开发和临床试验的见解
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-09-07
delete0
PREAI
deleteMadison R. McGann; Timothy F. Platts-Mills; Charles J. Gerardo
delete分享
delete收藏
Up and coming early phase CAR T-cell therapy for treating relapsed or refractory large B-cell lymphoma新兴的早期CAR T细胞疗法用于治疗复发或难治性大B细胞淋巴瘤
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-09-02
delete0
deleteOAAI
deleteDasom Lee; Masooma Rana; Arvin Esmali; Saurabh Dahiya
delete分享
delete收藏
HLD-0915: Could it be the breakthrough drug we need for metastatic prostate cancer?HLD-0915：它是否是我们治疗转移性前列腺癌所需的突破性药物？
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-29
delete0
deleteOAAI
deleteJakob R. Nypaver; Pedro C. Barata
delete分享
delete收藏
Peripheral cannabinoid-1 receptor antagonists in clinical development: therapeutic potential for the management of obesity and related metabolic disorders外周大麻素-1受体拮抗剂的临床开发：治疗肥胖及相关代谢紊乱的潜力
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-21
delete0
deleteOAAI
deleteJonanne Talebloo; Esha Chawla; Donya Shahamati; Swas Shiv; Kishore M. Gadde
delete分享
delete收藏
Taxane therapy in mCRPC: current positioning and emerging strategies to overcome resistancemCRPC中的紫杉烷类疗法：当前定位及克服耐药性的新兴策略
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-20
delete0
PREAI
deleteLing Wang; Yanfeng Tang; Mingsheng Liu; Hongqing Zhou; Hao Zeng; Bo Tang
delete分享
delete收藏
How can we determine suitable combination immunotherapies for cancer by looking at the molecular targeting of each therapy?如何通过分析每种疗法的分子靶向作用来确定癌症的适宜联合免疫疗法？
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-20
delete0
deleteOAAI
deleteNicole Sala; Giovanni Dalla Via; Giacomo De Micheli; Dario Trapani; Giuseppe Curigliano
delete分享
delete收藏
Telisotuzumab adizutecan for metastatic colorectal cancer: a c-MET-targeted antibody–drug conjugate with a topoisomerase inhibitor payload替利妥珠单抗阿迪zutecan用于转移性结直肠癌：一种靶向c-MET的抗体-药物偶联物，其载荷为拓扑异构酶抑制剂
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-19
delete0
deleteOAAI
deleteYuki Matsubara; Akihito Kawazoe
delete分享
delete收藏
Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates阿尔茨海默病II期临床试验中的认知增强药物：新兴的治疗候选药物
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-03
delete0
PREAI
deletePatricia Regina Manzine; Marina Carrasco; Thaís Antonia Alves Fernandes; Suelen Santos Alves; Laura Guzman; Leila Driouech; Mireia Millet-Sigalat; Norberto Garcia Cairasco; Jordi Olloquequi; M. Emilia Juan; Miren Ettcheto; Marcia Regina Cominetti; Antoni Camins
delete分享
delete收藏
Budigalimab: a viable option for patients with advanced solid tumors布吉利单抗：晚期实体瘤患者的一种可行选择
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-08-03
delete0
PREAI
deleteAlice Mogenet; Laurent Greillier
delete分享
delete收藏
Investigational IL-17A antagonist in the treatment of psoriatic arthritis - a review治疗银屑病关节炎的IL-17A拮抗剂研究进展——综述
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-07-29
delete0
deleteOAAI
deleteOsariemen Osunbor; Jan René Nkeck; Adewale O. Adebajo
delete分享
delete收藏
Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-16
delete0
PREAI
deleteMarie Kroemer; Morgane Lopez; Laura Mansi; Elsa Curtit
delete分享
delete收藏
Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges达里加巴特及其亚型选择性GABA-A调节：药理学、临床开发和转化挑战
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-16
delete0
PREAI
deleteLuigi Francesco Iannone; Marina Romozzi; Luca Pani; Fabio Tascedda
delete分享
delete收藏
The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates靶向药物偶联物在实体瘤中的发展历程：超越抗体药物偶联物
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-14
delete0
deleteOAAI
deleteStephen J. Walsh; Francesca Wood; Leslie R. DeMars; Gavin Bennett
delete分享
delete收藏
Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trialHL-300的安全性、耐受性和药代动力学研究：一项在健康中国成年人中进行的首次人体、随机、双盲、安慰剂对照的I期临床试验
deleteExpert Opinion on Investigational Drugs
IF4.1
delete2026-06-09
delete0
PREAI
deleteHui Qiu; Xingfei Zhang; Jie Huang; Lin Ye; Chan Zou; Jinlian Xie; Kunhong Deng; Qian Wu; Xiulin He; Congxin Liang; Yong Liu; Guang Yang; Guoping Yang; Chengxian Guo
delete分享
delete收藏